Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with an insidious onset for which reliable early biomarkers remain limited. The authors reasoned that ultra-early molecular alterations relevant to later AD susceptibility may be reflected in maternal biofluids during pregnancy. Because urine collection is fully noninvasive, repeatable, and sensitive to systemic changes, they applied urinary proteomics to test whether maternal urine can mirror molecular signatures related to fetal AD susceptibility. The primary objective was to profile dynamic temporal changes in the maternal urinary proteome across gestation when fetuses carry paternally inherited AD-causing mutations.
The experimental group was generated by mating wild-type female mice with 3xTg transgenic male mice, producing pregnant dams carrying fetuses heterozygous for the 3xTg-AD genotype. A control (blank) group consisted of wild-type male–female matings. Urine samples were collected consecutively at 10 defined gestational time points, spanning gestational day 1 (D1) through D19. The sampling strategy enabled sequential, within-gestation monitoring of the maternal urinary proteome to detect early and evolving differences between groups.
Label-free quantitative proteomics was employed to identify proteins with differential expression between the maternal groups at the sampled time points. Following protein identification and quantification, the authors performed comparative analyses to determine which urinary proteins differed between dams carrying heterozygous AD-susceptible fetuses and control pregnancies. They performed permutation testing to assess whether observed intergroup differences could be attributed to random noise; the permutation tests supported that the intergroup differences were not random.
The results demonstrated that stable intergroup differential proteins were detectable as early as the implantation stage (D1). Differential protein profiles were present throughout the entire gestation window sampled (D1–D19). The quantity of differential proteins and their expression trends showed marked temporal dynamics, indicating evolving molecular responses during pregnancy rather than a single transient change. These dynamic patterns suggest that paternal AD-linked mutations can trigger systemic molecular responses in the maternal organism at very early embryonic stages and that those responses persist and change across gestation.
To interpret the functional context of the differential proteins, the study applied Gene Ontology (GO) enrichment analysis. GO analysis was used to map temporally varying differential proteins to biological processes, providing insight into the likely pathways and systems implicated by the urinary proteomic changes. The source text reports that GO enrichment analysis was carried out to interpret temporal biological processes, but specific GO terms, pathway names, or enriched processes were not detailed in the available abstract.
The authors conclude that maternal urine can serve as a window into fetal susceptibility to Alzheimer’s disease, proposing maternal urinary proteomic signatures as a foundation for future prenatal noninvasive monitoring biomarker research. The study provides animal experimental data supporting the concept that prenatal paternal inheritance of AD mutations produces detectable maternal systemic molecular responses early in embryogenesis. These observations are positioned as relevant to investigations of the embryonic origins of AD and for guiding subsequent biomarker screening efforts.
This report is a preprint and has not undergone peer review. The abstract provides a summary of experimental approach and principal findings but does not include detailed data, specific protein identities, numeric effect sizes, sample sizes, cohort characteristics, technical parameters of the proteomic workflow, or the exact GO terms enriched; those details were not reported in the provided source text. Therefore, claims about specific proteins, their fold changes, or clinical translational readiness cannot be evaluated from the abstract alone. Additional peer-reviewed publication and independent validation will be needed to confirm the reproducibility, specificity, and potential clinical utility of the reported maternal urinary signatures.